Immunotherapy for acute-on-chronic liver failure
10.3969/j.issn.1001-5256.2021.11.046
- VernacularTitle:慢加急性肝衰竭的免疫治疗
- Author:
Xiaobin QIN
1
;
Rongzhen ZHANG
2
;
Cong WU
1
;
Shenglan ZENG
1
;
Yingyu LE
1
;
Dewen MAO
2
Author Information
1. Graduate School, Guangxi University of Chinese Medicine, Nanning 530001, China
2. Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China
- Publication Type:Reviews
- Keywords:
Acute-On-Chronic Liver Failure;
Immunomodulation;
Liver Regeneration;
Pharmaceutical Preparations;
Liver, Artificial
- From:
Journal of Clinical Hepatology
2021;37(11):2696-2700
- CountryChina
- Language:Chinese
-
Abstract:
Acute-on-chronic liver failure (ACLF) is a life-threatening disease with a high risk of multiple organ failure, sepsis, and death. ACLF activates innate and acquired immune responses in human body and thus leads to the progression of persistent systemic inflammatory response syndrome and multiple organ dysfunction, leading to the high mortality rate of this disease. Dysregulated immune response plays a key role in disease progression, and immunotherapy may help to target immune-mediated organ damage and inhibit the progression of liver failure. This article reviews the role and mechanism of drugs and means with a potential immune regulatory effect in ACLF, in order to provide a reference for immunotherapy for ACLF.
